Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Japan Adult Guardianship Law Association Inaugurated
November 24, 2003
-
ARCHIVE Chugai: Cost-cutting Efforts Produce Better-than-Expected Profits
November 24, 2003
-
ARCHIVE REGULATORY NEWS IN BRIEF
November 24, 2003
-
ARCHIVE Yamanouchi: Sales Up 2.8%, Attributable to Sales Growth of Harnal, Lipitor
November 24, 2003
-
ARCHIVE Council for Regulatory Reform May Be Replaced with More Powerful Machine: Mr Miyauchi
November 24, 2003
-
ARCHIVE Sankyo: Mevalotin Boosts Domestic, Overseas Sales
November 24, 2003
-
ARCHIVE FPMAJ Wants Gov't to Maintain Price Reduction Rules for Long-Listed Drugs
November 24, 2003
-
ARCHIVE Semi-annual Business Results
November 24, 2003
-
ARCHIVE E2D, E5/Q&A Reach Step 4, Q5E, E2E Step 2: ICH-6
November 24, 2003
-
ARCHIVE BULLETIN
November 24, 2003
-
ARCHIVE A 4%-Combined Reduction in Medical Fees, NHI Prices Called for by MOF
November 24, 2003
-
ARCHIVE WORLD NEWS IN BRIEF
November 24, 2003
-
ARCHIVE In Transition from Old Products to New Introductions: Prof. Hohbach of NBI
November 24, 2003
-
ARCHIVE BUSINESS NEWS IN BRIEF
November 24, 2003
-
ARCHIVE MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 24, 2003
-
ARCHIVE Kirin Preparing for Fully Independent Marketing from 2005
November 24, 2003
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
November 24, 2003
-
ARCHIVE 9-month Business Results
November 24, 2003
-
ARCHIVE DIAGNOSTIC NEWS IN BRIEF
November 24, 2003
-
ARCHIVE Toyama Chemical: Business Hit by Delay in TTP's Marketing Activities
November 24, 2003
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…